What topics does this cannabis study cover?

This study covers research on: Neuroprotection, Inflammation.

Where was this research published?

Published in ACS chemical neuroscience on April 15, 2026.

CBD combined with BDNF shows promise for early Alzheimer's prevention

Q: What did this research study find?

Researchers tested a novel combination therapy using *cannabidiol (CBD)* and plasmid brain-derived neurotrophic factor (*pBDNF*) in young 5XFAD mice, an established model of Alzheimer's Disease. The treatment used specially engineered nanoparticles designed to deliver both compounds directly to the

Cannabidiol and pBDNF Cotreatment Attenuates Pathological Symptoms and Improves Cognition in 3 month-Old 5XFAD Mice.

ACS chemical neuroscience • April 15, 2026 • Moderately Relevant

🤖

AI Summary

Researchers tested a novel combination therapy using cannabidiol (CBD) and plasmid brain-derived neurotrophic factor (pBDNF) in young 5XFAD mice, an established model of Alzheimer's Disease. The treatment used specially engineered nanoparticles designed to deliver both compounds directly to the brain. The rationale was that early intervention—before symptoms appear—might prevent the disease progression that becomes irreversible by the time cognitive decline is noticeable. This contrasts with current AD treatments that typically begin after significant brain damage has already occurred.

The results were striking: four weekly doses of the combined CBD and pBDNF treatment reduced amyloid plaques by over 3-fold compared to controls, with highly significant statistical measures (p < 0.0001). The therapy also dramatically reduced neuroinflammation, cutting levels of pro-inflammatory cytokines TNF-α and IL-1β by approximately 2.5-fold and reducing microglial activation by 2.15-fold. These outcomes are significant because neuroinflammation is now recognized as a major driver of Alzheimer's progression, working alongside the hallmark amyloid plaques and tau tangles.

Beyond reducing pathology, the combination therapy improved cognitive function by promoting synaptic markers and adult neurogenesis in the hippocampus—the brain region critical for learning and memory. This study suggests that CBD's anti-inflammatory and neuroprotective properties, when combined with BDNF's cognitive maintenance effects, create a synergistic approach to halting AD before irreversible damage occurs. While this research is still in animal models, it opens exciting possibilities for early-intervention strategies in humans at genetic or lifestyle risk for Alzheimer's.

📄 Original Abstract

The marginal efficiency observed with the existing therapies in Alzheimer's Disease (AD) can be attributed to the timing of the treatment. The beneficiaries of symptomatic or disease-modifying therapy for AD are mild-cognitive-impairment (MCI) or late-stage dementia patients. At this stage, the pathological features are already advanced and irreversible, as the shift in biomarker levels starts in a continuum 15-20 years prior. Early intervention, therefore, is a plausible solution to this issue. Consequently, we selected 3 month-old 5XFAD AD mice as an early intervention model. We administered cannabidiol (CBD) and plasmid brain-derived neurotrophic factor (BDNF) encapsulated in liposome nanoparticles, functionalized with penetratin and mannose for brain-targeting, as a therapy. Neuroinflammation is emerging as a key driver of AD progression by its interaction with amyloid plaques and phosphorylated tau. Therefore, CBD, which is anti-inflammatory and neuroprotective, was used. BDNF, a synaptic modulation and cognitive maintenance agent, is declined and, thus, aggravates pathology and cognition in AD. BDNF expressed from the liposome nanoparticles supplements the reduced BDNF and aids in ameliorating AD pathology. We found four weekly doses of our formulation reduced the amyloid burden by 3.04-fold (p-value < 0.0001), declined pro-inflammatory cytokines TNF-α by 2.51-fold (p-value < 0.0001), IL-1β by 2.34-fold (p-value < 0.0001) and microglial activation by 2.15-fold (p-value < 0.0001) than saline controls. In addition, it increased the synaptic markers level and promoted adult hippocampal neurogenesis, eventually improving cognitive functions. These findings suggest the use of CBD and pBDNF has a potential therapeutic combination for AD management if intervened early.

Paper Type

📄 Research

Publication

Journal: ACS chemical neuroscience
Published: April 15, 2026
PMID: 41924980
DOI: 10.1021/acschemneuro.5c01009

Authors (5)

Bivek Chaulagain Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, North Dakota 58105, United States.
Avinash Gothwal Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, North Dakota 58105, United States.
Arun Kumar Mahanta Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, North Dakota 58105, United States.
Yagna P R Jarajapu Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, North Dakota 58105, United States.
Jagdish Singh Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, North Dakota 58105, United States.